Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01521793 · ClinicalTrials.gov registry record · Phase 1
Repeated Treatments of QLT091001 in Subjects With Leber Congenital Amaurosis or Retinitis Pigmentosa (Extension of Study RET IRD 01)
A Phase 1 study, sponsored by QLT.
- Completed
- Registry status
- Phase 1
- Development phase
- 27
- Enrollment target
NCT01521793 is a Phase 1 study that has completed, run by QLT. The registered enrollment target is 27 participants.
The verdict
NCT01521793, a Phase 1 study, has completed, sponsored by QLT.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 27 participants
- Enrollment target
Study Summary
The purpose of this study is: * To evaluate the safety of up to 3 additional courses of oral QLT091001 administered once daily for 7 days in subjects treated previously with a single 7-day course of QLT091001 in Study RET IRD 01 * To evaluate whether up to 3 additional courses of oral QLT091001 administered once daily for 7 days can maintain or improve visual function.
Interventions
- DRUG QLT091001
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2012-01 |
| Est. Completion | 2014-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01521793
The ClinicalTrials.gov registry entry for NCT01521793 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is QLT, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which QLT091001 is the first listed.
NCT01521793 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01521793 about?
NCT01521793 is a clinical study titled "Repeated Treatments of QLT091001 in Subjects With Leber Congenital Amaurosis or Retinitis Pigmentosa (Extension of Study RET IRD 01)". The purpose of this study is: * To evaluate the safety of up to 3 additional courses of oral QLT091001 administered once daily for 7 days in subjects treated previously with a single 7-day course of QLT091001 in Study RET IRD 01 * To evaluate whether up to 3 additional courses of oral QLT091001 adm...
What is the current status of trial NCT01521793?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 27 participants. The study started on 2012-01. Estimated completion is 2014-06.
What interventions are being tested in trial NCT01521793?
The interventions under investigation include: QLT091001 (DRUG).
Who is sponsoring clinical trial NCT01521793?
This trial is sponsored by QLT, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.